Profile data is unavailable for this security.
About the company
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
- Revenue in JPY (TTM)27.97bn
- Net income in JPY2.44bn
- Incorporated2006
- Employees603.00
- LocationPeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
- Phone+81 442701300
- Websitehttps://www.peptidream.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio-Thera Solutions Ltd | 15.08bn | -7.86bn | 175.13bn | 1.17k | -- | 7.55 | -- | 11.61 | -0.8957 | -0.8957 | 1.72 | 2.64 | 0.3099 | 0.9439 | 6.06 | 609,647.70 | -16.15 | -23.62 | -23.70 | -30.81 | 71.41 | 79.76 | -52.13 | -106.72 | 0.8258 | -367.55 | 0.3515 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| InnoCare Pharma Ltd | 15.70bn | -13.42bn | 183.21bn | 1.09k | -- | 1.03 | -- | 11.67 | -0.4041 | -0.4041 | 0.4725 | 4.38 | 0.073 | 1.39 | 3.39 | 732,144.50 | -6.38 | -13.41 | -8.08 | -15.36 | 82.61 | 85.99 | -87.42 | -172.16 | 4.13 | -- | 0.1582 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
| Clarity Pharmaceuticals Ltd | 0.00 | -3.08bn | 192.33bn | -- | -- | 30.39 | -- | -- | -0.1167 | -0.1167 | 0.00 | 0.2017 | 0.00 | -- | -- | -- | -41.34 | -- | -45.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.57 | -- | -- | -- |
| Joinn Laboratories China Co Ltd | 49.44bn | -1.34bn | 202.64bn | 2.50k | -- | 1.30 | -- | 4.10 | -0.0862 | -0.0862 | 3.12 | 10.75 | 0.23 | 0.6906 | 8.14 | -- | -0.6856 | 8.99 | -0.8219 | 11.07 | 39.46 | 46.76 | -2.98 | 32.01 | 3.51 | 0.9996 | 0.0079 | 23.81 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
| Mabwell Shanghai Bioscience Co Ltd | 4.06bn | -21.58bn | 204.17bn | 1.49k | -- | 4.00 | -- | 50.33 | -2.55 | -2.55 | 0.4789 | 6.02 | 0.0412 | 0.0472 | 16.79 | 128,337.60 | -22.02 | -37.61 | -26.37 | -45.95 | 96.84 | 81.54 | -534.78 | -2,112.26 | 1.96 | -- | 0.442 | -- | 361.03 | 27.88 | -10.28 | -- | 17.35 | -- |
| Polaris Group LLC | 164.37m | -7.93bn | 230.91bn | -- | -- | 6.76 | -- | 1,404.81 | -2.28 | -2.28 | 0.0472 | 9.78 | 0.0038 | -- | 4.58 | -- | -18.71 | -16.55 | -20.12 | -17.96 | -24.76 | -- | -4,904.26 | -12,960.21 | 12.67 | -- | 0.141 | -- | 16.18 | -- | -37.05 | -- | 50.45 | -- |
| RemeGen Co Ltd | 22.88bn | -32.13bn | 241.63bn | 3.62k | -- | 2.01 | -- | 10.56 | -3.03 | -3.03 | 2.16 | 6.90 | 0.1864 | 0.4005 | 4.31 | 321,372.60 | -26.17 | -18.66 | -31.75 | -23.75 | 76.48 | 81.94 | -140.43 | -102.88 | 1.31 | -64.32 | 0.2682 | -- | 40.16 | 148.65 | -51.30 | -- | 59.07 | -- |
| Dizal Jiangsu Pharmaceutical Co Ltd | 3.66bn | -23.16bn | 325.16bn | 581.00 | -- | 22.02 | -- | 88.86 | -2.67 | -2.67 | 0.422 | 1.68 | 0.1008 | 0.3215 | 6.78 | 297,086.40 | -63.79 | -46.02 | -82.62 | -52.99 | 96.41 | 57.53 | -632.90 | -2,081.54 | 1.74 | -- | 0.4557 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
| Peptidream Inc | 27.97bn | 2.44bn | 344.59bn | 603.00 | 140.64 | 8.59 | 70.35 | 12.32 | 18.85 | 18.85 | 215.77 | 308.51 | 0.4323 | 4.20 | 5.14 | 46,391,190.00 | 3.77 | -- | 4.38 | -- | 59.16 | -- | 8.73 | -- | 3.23 | 2.59 | 0.3505 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
| Sinocelltech Group Ltd | 46.03bn | -3.58bn | 348.95bn | 2.33k | -- | -- | -- | 7.58 | -0.3791 | -0.3791 | 4.88 | -1.16 | 0.761 | 0.3743 | 6.86 | 930,592.90 | -5.93 | -40.17 | -15.48 | -74.63 | 96.35 | 95.42 | -7.79 | -108.20 | 0.4649 | 3.33 | 1.23 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
| Shanghai Allist Pharmaceuticals Co Ltd | 52.67bn | 19.41bn | 488.65bn | 1.04k | 25.18 | 5.33 | -- | 9.28 | 2.03 | 2.03 | 5.52 | 9.60 | 0.6091 | 3.16 | 10.51 | 2,379,802.00 | 22.44 | 0.6405 | 24.19 | 0.6933 | 94.48 | 96.42 | 36.84 | 2.54 | 8.22 | -- | 0.0004 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
Data as of Jul 29 2024. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY
28.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 15 Dec 2023 | 9.80m | 7.54% |
| Taiyo Pacific Partners LPas of 31 Dec 2023 | 6.58m | 5.06% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 14 Jul 2023 | 4.44m | 3.42% |
| Baillie Gifford & Co.as of 30 Jun 2024 | 3.26m | 2.51% |
| Nomura Asset Management Co., Ltd.as of 31 May 2024 | 3.24m | 2.50% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 3.09m | 2.37% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.09m | 1.61% |
| Nikko Asset Management Co., Ltd.as of 14 Jul 2023 | 1.80m | 1.39% |
| Daiwa Asset Management Co. Ltd.as of 28 Jun 2024 | 1.54m | 1.18% |
| Alma Capital Investment Management SA (UK)as of 31 Dec 2023 | 1.36m | 1.05% |
More ▼
Data from 31 Dec 2023 - 25 Jul 2024Source: FactSet Research Systems Inc.
